Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target
Author:
Funder
University of Rome La Sapienza
Ministero dell'Università e della Ricerca
Government of Italy Commission for the Selection of Excellence University Departments
Ministero dell’Istruzione, dell’Università e della Ricerca
Publisher
Elsevier BV
Reference238 articles.
1. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia;Advani;Leuk. Res.,2010
2. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis;Ageberg;Genes Chromosomes Cancer,2008
3. HNRNPA2B1 is a mediator of m(6)a-dependent nuclear RNA processing events;Alarcón;Cell,2015
4. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia;Aldoss;Haematologica,2018
5. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis;Alvarez-Dominguez;Blood,2017
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3